Adult Malignant Glioma Therapeutics Market Size (2024 - 2029)

The adult malignant glioma therapeutics market is expected to experience growth due to several key factors. The high incidence of brain cancer and malignant gliomas globally is a significant driver of market expansion. Additionally, increased funding and support from government organizations for research and development are contributing to the market's growth trajectory. Strategic initiatives by market players, such as product approvals and partnerships, are also enhancing market dynamics. Despite these positive trends, challenges such as a decreasing preference for chemotherapy and low approval rates for new therapeutics may hinder market growth.

Market Size of Adult Malignant Glioma Therapeutics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Adult Malignant Glioma Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 9.60 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Adult Malignant Glioma Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Adult Malignant Glioma Therapeutics Market Analysis

The adult malignant glioma therapeutics market is projected to register a CAGR of 9.6% during the forecast period.

The COVID-19 pandemic has caused widespread disruption in cancer care, including delays in treatment as well as the suspension of clinical trials. For instance, according to an article published in June 2021, the provision of oncology services was considerably reduced during the COVID pandemic. COVID-19 also had an adverse impact on people with malignant brain tumors. For instance, an article published in Acta Medica in July 2022 stated that due to immunodepression related to tumor disease and anti-cancer treatments, cancer patients were more vulnerable to COVID-19 and had a higher risk of severe complications requiring intensive care. However, the market recovered in the past few years since the restrictions were lifted and trials for the development of glioma therapeutics resumed. COVID-19 has a negligible impact on the adult malignant glioma therapeutics market in the current scenario and is expected to show a stable growth rate during the forecast period.

The high burden of brain cancer and malignant gliomas globally is expected to propel market growth. For instance, according to the Canadian Cancer Society 2022 update, 3,200 Canadians were estimated to be diagnosed with brain and spinal cord cancer in 2022. Also, as per the Australian Institute of Health and Welfare 2022 report, the estimated age-standardized incidence rate for brain cancer was 6.4 cases per 100,000 persons (8.1 for males and 4.8 for females) in 2022.

Furthermore, the rising funding and engagement of government organizations to expedite the malignant gliomas therapeutics research and development (R&D) is also contributing significantly to the market growth. For instance, in October 2022, the Australian Government provided more than USD 5.4 million to support brain cancer research. The funding is from the Medical Research Future Fund (MRFF). Also, in September 2021, the NCI-funded Glioblastoma Therapeutics Network (GTN) reported working collaboratively to develop new treatments for malignant gliomas. The rising funding and partnership for the development of innovative therapeutics are expected to propel market growth.

The strategic initiatives by market players, such as product approvals, launches, and partnerships to expand adult malignant gliomas therapeutics, are expected to augment the market growth. For instance, in December 2021, Sapience Therapeutics, Inc. was granted Fast Track Designation to its lead program investigating ST101 for treating recurrent glioblastoma (GBM) by the United States Food and Drug Administration (FDA). The fast-track designation expedites the review of a drug for treating serious conditions, thereby propelling the market growth.

Therefore, owing to the factors such as the high burden of brain cancer, rising R&D spending, and product approvals and launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the diminishing preference for chemotherapy and low approval rates for novel therapeutics for glioma is estimated to restrain the market growth.

Adult Malignant Glioma Therapeutics Industry Segmentation

As per the scope of the report, malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. The Adult Malignant Glioma Therapeutics Market is Segmented by Type of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, and Other Types of Diseases), Therapy (Chemotherapy, Targeted Drug Therapy, and Radiation Therapy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type of Disease
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types of Disease
By Therapy
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Other Types of Chemotherapy
Targeted Drug Therapy
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Other Monoclonal Antibodies
Radiation Therapy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Adult Malignant Glioma Therapeutics Market Size Summary

The adult malignant glioma therapeutics market is poised for significant growth, driven by the high global burden of brain cancer and the increasing focus on research and development. The market has shown resilience following the disruptions caused by the COVID-19 pandemic, with a return to normalcy as clinical trials and therapeutic developments resumed. The market's expansion is further supported by substantial funding from government and non-government organizations, aimed at accelerating research and innovation in glioma treatments. Strategic initiatives by key market players, including product approvals and partnerships, are also contributing to the market's positive trajectory. Despite challenges such as the diminishing preference for chemotherapy and low approval rates for novel therapeutics, the market is expected to witness steady growth over the forecast period.

North America is anticipated to dominate the adult malignant glioma therapeutics market, attributed to the high prevalence of gliomas, robust funding for research, and a concentration of market players in the region. The region's market growth is bolstered by significant investments in research and development, aimed at developing advanced therapeutics for brain cancer. The competitive landscape of the market is moderately competitive, with major players like Merck & Co. Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company holding significant market shares. Collaborative efforts, such as those between Stanford University and The Invus Group, are expected to drive further advancements in glioma treatments, enhancing the market's growth prospects.

Explore More

Adult Malignant Glioma Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Burden of Brain Cancer and Malignant Gliomas

      2. 1.2.2 Rising Funding for Research and Development

    3. 1.3 Market Restraints

      1. 1.3.1 Diminishing Preference for Chemotherapy

      2. 1.3.2 Low Approval Rates for Novel Therapeutics for Glioma

    4. 1.4 Porter Five Forces

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value- USD million)

    1. 2.1 By Type of Disease

      1. 2.1.1 Glioblastoma Multiforme

      2. 2.1.2 Anaplastic Astrocytoma

      3. 2.1.3 Anaplastic Oligodendroglioma

      4. 2.1.4 Anaplastic Oligoastrocytoma

      5. 2.1.5 Other Types of Disease

    2. 2.2 By Therapy

      1. 2.2.1 Chemotherapy

        1. 2.2.1.1 Temozolomide

        2. 2.2.1.2 Bevacizumab

        3. 2.2.1.3 Carmustine

        4. 2.2.1.4 Other Types of Chemotherapy

      2. 2.2.2 Targeted Drug Therapy

        1. 2.2.2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors

        2. 2.2.2.2 Other Monoclonal Antibodies

      3. 2.2.3 Radiation Therapy

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Adult Malignant Glioma Therapeutics Market Size FAQs

The Adult Malignant Glioma Therapeutics Market is projected to register a CAGR of 9.60% during the forecast period (2024-2029)

Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories and Azurity Pharmaceuticals, Inc. are the major companies operating in the Adult Malignant Glioma Therapeutics Market.

Adult Malignant Glioma Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)